Transgene: Bgl II-Sma I fragment of APP-695 cDNA (bb 1769-2959) was cloned into
a modified form of plasmid pRSV
Promoter: in which the Rous sarcoma virus promoter is replaced with the dystrohpin
neural promoter.
Coding Region: Transgene is place downstream simian virus 40 splice and polyadenylylation
sequences.
Flag Sequence (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys), preceded by a methionine, to the
N-terminus of APP-C100
Mouse Strain: C58BL/6 x SJL.
Neuropathological Analysis:
As early as 4.5 months of age, APP-C100 mice showed appearance of oddly shaped secondary
lysosomes that were immunoreactive with antibodies directed against portions of
APP-C100. In older mice, these structures took the form of abundant deposits
of dense, granular material in the hippocampal formation.
Numerous pyramidal cells in various states of degeneration could be found throughout
the dentate gyrus and ammon's horn in the 23-month-old and 28-month-old APP-C100
mice, respectively.
At age of 1 year, C100 mice display a significant number of large lucent pyramidal
neurons containing irregular cytoplasmic accumulations of atypical secondary lysosomes,
and an increased neurofilament concentration in unmyelinated axons.
Cytoskeletal and synaptic degeneration observed in the APP-C100 mice.
FLAG-APP-C100: The FLAG sequence is used to distinguish the transgene product
from the endogenous APP gene product.
FLAGAPP-C100 is less prone to aggregate than was C100, and that it bound with greater
affinity than did C100 to a specific PC12 cell receptor that mediates the C100 toxicity,
which suggests that C100, unlike Ab, is most deadly to
neurons when it is in a nonaggregated form. Also unlike Ab,
toxicity of C100 is receptor mediated and pH dependent.
No gross motor or sensory abnormalities were apparent in the mice.
All the mice exhibited normal righting, grasping and placing reflexes. None
of the mice floated excessively during any of the swim trials. No significant differences
in Dark-cycle locomotor activities observed between transgenic and control mice.
In Morris water maze, homozygous transgenic mice expressing Flag epitope-tagged
APP-C100, relative to heterozygote Tg and control, showed significant deficits in
cued, spatial and reversal performance. The degree of impairment of spatial learning
in homozygous mice appears to be age-dependent.
Among heterozygotes, females were relatively more impaired in their spatial learning
than were males.
Contact Dr. Rachael Neve
202 MRC
McLean Hospital
115 Mill Street
Belmont, MA 02178
Patents:
|
5,672,805
|
Transgenic mice expressing the neurotoxic C-terminus of .beta.-amyloid precursor
protein
|
The Regents of the University of California/
Neve; Rachael L.
|
7/18/91
|
9/30/97
|
|
5,849,999
|
Transgenic non-human mice expressing Flag-APP-C100 protein develop alzheimer's disease
brain morphology and behavior
|
The McLean Hospital Corporation; Wellesley College /
Neve; Rachael L.; Berger-Sweeney; Joanne
|
10/16/96
|
12/15/98
|
|
5,894,078
|
Transgenic mouse expressing C-100 app
|
Advanced Bioconcept, Inc./
Nalbantoglu; Josephine; Julien; Jean-Pierre; Shapiro; Matthew
|
2/26/96
|
4/13/99
|
Reference
Primary:
Neve RL, Boyce FM, McPhie DL, Greenan J, Oster-Granite ML. Transgenic mice expressing
APP-C100 in the brain. Neurobiol Aging 1996 Mar-Apr;17(2):191-203.
Abstract.
Associated:
Oster-Granite ML, McPhie DL, Greenan J, Neve RL. Age-dependent neuronal and synaptic
degeneration in mice transgenic for the C terminus of the amyloid precursor protein.
J Neurosci 1996 Nov 1;16(21):6732-41.
Abstract.
Kammesheidt A, Boyce FM, Spanoyannis AF, Cummings BJ, Ortegon M, Cotman C, Vaught
JL, Neve RL. Deposition of beta/A4 immunoreactivity and neuronal pathology in transgenic
mice expressing the carboxyl-terminal fragment of the Alzheimer amyloid precursor
in the brain. Abstract.
Berger-Sweeney J, McPhie DL, Arters JA, Greenan J, Oster-Granite ML, Neve RL. Impairments
in learning and memory accompanied by neurodegeneration in mice transgenic for the
carboxyl-terminus of the amyloid precursor protein. Brain Res Mol Brain Res 1999
Mar 20;66(1-2):150-62.
Abstract.
|